New stomach ulcer drug put to the test in healthy volunteers
NCT ID NCT07385235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial compares two versions of a drug called AD-115A and AD-1151, designed to treat gastric ulcers. 46 healthy adults will receive a single dose of each version to see how the drug moves through the body and to check for side effects. The goal is to find out which version works better and is safer before testing in patients with ulcers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AD-115A and AD-1151 (two formulations of the same drug)
- What this could lead to
- If successful, this study could help determine which formulation is better absorbed and safer, potentially leading to a more effective treatment for gastric ulcers.
- What could go wrong
- This is an early Phase 1 trial in healthy volunteers, not patients. It only measures drug levels and safety, not whether the drug actually treats ulcers. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ULCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H PLUS YANGJI HOSPITAL, Seoul
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.